Drug intelligence / Profile preview

BR008

Development stage: Preclinical
Lead developer: Xiyuan Anjian Pharmaceutical

Overview

BR008 is an investigational drug candidate initially developed by Xiyuan Anjian Medicine (Shanghai) for the treatment of nervous system diseases, with a primary focus on neuralgia. As of March 2025, its highest reported development status is preclinical. The specific mechanism of action, molecular target(s), and modality have not been publicly disclosed. There are no available details regarding its chemical structure or pharmacological class. No evidence suggests that BR008 is related to the NRG-BR008/HERO clinical trial in breast cancer; these refer to different entities[3].

Beyond the preview

Go deeper on BR008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR008.

Explore the full profile